Notice NOT-GM-20-022 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MD-20-006 from the NIH Guide for Grants and Contracts. The purpose of the Research Centers in Minority Institutions (RCMI) Program is to expand the national capacity for research in the health sciences by providing cooperative agreement support to institutions that offer doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. The primary goals of the RCMI specialized centers are to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research; (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of new and early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; and (5) establish sustainable relationships with community-based organizations that will partner with the RCMI Institution.

Notice NOT-EY-20-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-20-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide continuing support for the Informatics, Coordination and Service Center (ICSC) unit of the Mutant Mouse Resource and Research Centers (MMRRC) consortium. The ICSC is expected to provide informatics and coordinating services to the MMRRC consortium and biomedical researchers. These services include maintenance and further development of a public website portal and Customer Service Center; operation of the order processing system; review and processing of applications from donating investigators; facilitation of interactions with biomedical investigators, informatics services, database activities, and the archive of MMRRC documents and files; coordination of requests to donate mouse strains to the MMRRCs and to order mouse strains from the MMRRCs; oversight of marketing efforts; and completion of monthly and yearly metrics reports. Moreover, the ICSC will host and actively participate in the monthly teleconference, annual consortium meeting, and compose reports and summaries from these forums as requested by MMRRC consortium members or NIH staff.

Notice NOT-LM-20-005 from the NIH Guide for Grants and Contracts

F. Hoffmann-La Roche AG: Data have the power to answer more than one question and enable multiple discoveries, but only if Findable, Accessible, Interoperable, and Reusable ( Switzerland (CH)

Notice NOT-ES-20-011 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-032 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-033 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-011 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-005 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-010 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-033 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-036 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-752 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-029 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-028 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-20-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is aimed at discovering, characterizing the selectivity and sensitivity, and externally validating biological measures to be used for assessing, prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.